Supernus Pharmaceuticals, Inc. (SUPN) Institutional Ownership & Insider Trading

332 institutions reported holding Supernus Pharmaceuticals, Inc. shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 26 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

SUPNSupernus Pharmaceuticals, Inc.Follow SUPN — free

Drug Manufacturers - Specialty & Generic · Healthcare

—

Price chart with a free account

Market cap: 2.4B
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 29 Oct, in 5 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

332 institutions held —% of the shares. Across filers that reported both quarters, shares held changed +3.6%.

Largest moves, shares (millions)

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters

Quarter	Holders	Shares held, M	Change	Increased	New	Decreased	Closed
Jun 26	332	60	+3.6%	115	33	100	26
Mar 26	325	58	+2.4%	106	31	105	36
Dec 25	330	57	-6.0%	99	41	103	24
Sep 25	305	58	-2.6%	84	46	106	36
Jun 25	292	59	+0.3%	109	32	78	27
Mar 25	287	59	-0.5%	102	26	80	27
Dec 24	290	59	-1.2%	85	30	78	15
Sep 24	270	60	+2.4%	76	36	76	14

Supernus Pharmaceuticals, Inc. — questions

Who owns Supernus Pharmaceuticals, Inc. stock?: 332 institutions reported Supernus Pharmaceuticals, Inc. shares in 13F filings for the quarter ended 2026-06-30. The largest: BlackRock, Inc. (16.1%), MILLENNIUM MANAGEMENT LLC (6.6%), VANGUARD PORTFOLIO MANAGEMENT LLC (5.7%).
Are Supernus Pharmaceuticals, Inc. insiders buying or selling?: 26 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from Supernus Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.